Cargando…

Pediatric CIDP: Diagnosis and Management. A Single-Center Experience

Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare acquired polyneuropathy that especially among youngest children should be differentiated with hereditary neuropathies. Even though upon diagnosis treatment options are similar in children and adults, diagnostic challenges...

Descripción completa

Detalles Bibliográficos
Autores principales: Łukawska, Małgorzata, Potulska-Chromik, Anna, Lipowska, Marta, Hoffman-Zacharska, Dorota, Olchowik, Beata, Figlerowicz, Magdalena, Kanabus, Karolina, Rosiak, Edyta, Kostera-Pruszczyk, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284159/
https://www.ncbi.nlm.nih.gov/pubmed/34276534
http://dx.doi.org/10.3389/fneur.2021.667378
_version_ 1783723342046429184
author Łukawska, Małgorzata
Potulska-Chromik, Anna
Lipowska, Marta
Hoffman-Zacharska, Dorota
Olchowik, Beata
Figlerowicz, Magdalena
Kanabus, Karolina
Rosiak, Edyta
Kostera-Pruszczyk, Anna
author_facet Łukawska, Małgorzata
Potulska-Chromik, Anna
Lipowska, Marta
Hoffman-Zacharska, Dorota
Olchowik, Beata
Figlerowicz, Magdalena
Kanabus, Karolina
Rosiak, Edyta
Kostera-Pruszczyk, Anna
author_sort Łukawska, Małgorzata
collection PubMed
description Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare acquired polyneuropathy that especially among youngest children should be differentiated with hereditary neuropathies. Even though upon diagnosis treatment options are similar in children and adults, diagnostic challenges are faced in the pediatric population. Methods: We conducted a retrospective analysis of clinical symptoms, nerve conduction study results, modes of treatment, and final outcome in 37 children aged 3.5–17 years with a final diagnosis of CIDP (18 girls, 19 boys). We established three groups of patients based on age at onset of CIDP: 0–4, 4–13, and 13–18 years. Follow-up ranged from 10 to 222 months. Results: In our analysis, 19/37 patients (51.4%) had an atypical presentation: distal variant of CIDP in 12/37 patients (32.4%) and pure motor variant of CIDP in 5/37 patients (13.5%), and one patient had a pure sensory variant (1/37, 2.7%). Furthermore, 3/37 patients (8.1%) had additional concurring symptoms, including involuntary movements of face muscles (1/37, 2.7%) or hand tremor (2/37, 5.4%). During the follow-up, 23/37 patients (62.2%) received intravenous immunoglobulin (IVIg); 22/37 patients (59.5%) received steroids, 6/37 patients (16.2%) received IVIg and steroids, and 12/37 patients (32.4%) received immunosuppressive drugs, mostly azathioprine, but also methotrexate and rituximab. One patient was treated with plasmapheresis. Complete remission was achieved in 19/37 patients (51.4%) with CIDP in its typical form. Remission with residual symptoms or minimal deficit was observed in 4/37 patients (10.8%), whereas 14/37 patients (37.8%) remain on treatment with gradual improvement. Conclusion: Childhood CIDP may occur in its typical form, but even ~50% of children can present as an atypical variant including distal, pure motor, or pure sensory. Most children have a good prognosis; however, many of them may require long-term treatment. This highlights the importance of an early diagnosis and treatment for childhood CIDP.
format Online
Article
Text
id pubmed-8284159
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82841592021-07-17 Pediatric CIDP: Diagnosis and Management. A Single-Center Experience Łukawska, Małgorzata Potulska-Chromik, Anna Lipowska, Marta Hoffman-Zacharska, Dorota Olchowik, Beata Figlerowicz, Magdalena Kanabus, Karolina Rosiak, Edyta Kostera-Pruszczyk, Anna Front Neurol Neurology Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare acquired polyneuropathy that especially among youngest children should be differentiated with hereditary neuropathies. Even though upon diagnosis treatment options are similar in children and adults, diagnostic challenges are faced in the pediatric population. Methods: We conducted a retrospective analysis of clinical symptoms, nerve conduction study results, modes of treatment, and final outcome in 37 children aged 3.5–17 years with a final diagnosis of CIDP (18 girls, 19 boys). We established three groups of patients based on age at onset of CIDP: 0–4, 4–13, and 13–18 years. Follow-up ranged from 10 to 222 months. Results: In our analysis, 19/37 patients (51.4%) had an atypical presentation: distal variant of CIDP in 12/37 patients (32.4%) and pure motor variant of CIDP in 5/37 patients (13.5%), and one patient had a pure sensory variant (1/37, 2.7%). Furthermore, 3/37 patients (8.1%) had additional concurring symptoms, including involuntary movements of face muscles (1/37, 2.7%) or hand tremor (2/37, 5.4%). During the follow-up, 23/37 patients (62.2%) received intravenous immunoglobulin (IVIg); 22/37 patients (59.5%) received steroids, 6/37 patients (16.2%) received IVIg and steroids, and 12/37 patients (32.4%) received immunosuppressive drugs, mostly azathioprine, but also methotrexate and rituximab. One patient was treated with plasmapheresis. Complete remission was achieved in 19/37 patients (51.4%) with CIDP in its typical form. Remission with residual symptoms or minimal deficit was observed in 4/37 patients (10.8%), whereas 14/37 patients (37.8%) remain on treatment with gradual improvement. Conclusion: Childhood CIDP may occur in its typical form, but even ~50% of children can present as an atypical variant including distal, pure motor, or pure sensory. Most children have a good prognosis; however, many of them may require long-term treatment. This highlights the importance of an early diagnosis and treatment for childhood CIDP. Frontiers Media S.A. 2021-07-02 /pmc/articles/PMC8284159/ /pubmed/34276534 http://dx.doi.org/10.3389/fneur.2021.667378 Text en Copyright © 2021 Łukawska, Potulska-Chromik, Lipowska, Hoffman-Zacharska, Olchowik, Figlerowicz, Kanabus, Rosiak and Kostera-Pruszczyk. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Łukawska, Małgorzata
Potulska-Chromik, Anna
Lipowska, Marta
Hoffman-Zacharska, Dorota
Olchowik, Beata
Figlerowicz, Magdalena
Kanabus, Karolina
Rosiak, Edyta
Kostera-Pruszczyk, Anna
Pediatric CIDP: Diagnosis and Management. A Single-Center Experience
title Pediatric CIDP: Diagnosis and Management. A Single-Center Experience
title_full Pediatric CIDP: Diagnosis and Management. A Single-Center Experience
title_fullStr Pediatric CIDP: Diagnosis and Management. A Single-Center Experience
title_full_unstemmed Pediatric CIDP: Diagnosis and Management. A Single-Center Experience
title_short Pediatric CIDP: Diagnosis and Management. A Single-Center Experience
title_sort pediatric cidp: diagnosis and management. a single-center experience
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284159/
https://www.ncbi.nlm.nih.gov/pubmed/34276534
http://dx.doi.org/10.3389/fneur.2021.667378
work_keys_str_mv AT łukawskamałgorzata pediatriccidpdiagnosisandmanagementasinglecenterexperience
AT potulskachromikanna pediatriccidpdiagnosisandmanagementasinglecenterexperience
AT lipowskamarta pediatriccidpdiagnosisandmanagementasinglecenterexperience
AT hoffmanzacharskadorota pediatriccidpdiagnosisandmanagementasinglecenterexperience
AT olchowikbeata pediatriccidpdiagnosisandmanagementasinglecenterexperience
AT figlerowiczmagdalena pediatriccidpdiagnosisandmanagementasinglecenterexperience
AT kanabuskarolina pediatriccidpdiagnosisandmanagementasinglecenterexperience
AT rosiakedyta pediatriccidpdiagnosisandmanagementasinglecenterexperience
AT kosterapruszczykanna pediatriccidpdiagnosisandmanagementasinglecenterexperience